Mark J. McKeage

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa et al. · Journal of Clinical Oncology · 2011 · 315 citations · Full text

Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer

Khine Nyein Myint, Riya Biswas, Yan Li et al. · Scientific Reports · 2019 · 261 citations · Full text

Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria

Mark J. McKeage, Lenushka Maharaj, Susan J. Berners‐Price · Coordination Chemistry Reviews · 2002 · 242 citations

Redox Signaling, Inorganic Chemistry, Medicinal Chemistry +10

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Lloyd R. Kelland, G Abel, Mark J. McKeage et al. · PubMed · 1993 · 224 citations

Chemoprevention Strategy, Active Platinum Drug, Pathology +18

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

Mark J. McKeage, Susan J. Berners‐Price, Peter Galettis et al. · Cancer Chemotherapy and Pharmacology · 2000 · 211 citations

Oxysterol, Biochemistry, Cellular Uptake +4